Currently out of the existing stock ratings of Stephen Unger, 67 are a BUY (90.54%), 6 are a HOLD (8.11%), 1 are a SELL (1.35%).

Stephen Unger

Work Performance Price Targets & Ratings Chart

Analyst Stephen Unger, currently employed carries an average stock price target met ratio of 87.36% that have a potential upside of 29.19% achieved within 134 days. Previously, Stephen Unger worked at NEEDHAM.

Stephen Unger’s has documented 127 price targets and ratings displayed on 13 stocks. The coverage was on Healthcare, Technology, Industrials sectors.

Most recent stock forecast was given on NEO, NeoGenomics at 29-Mar-2022.

Wall Street Analyst Stephen Unger

Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for NEO (NEOGENOMICS) at 1/3/2019. The price target of $14 was fulfilled within 6 days with a profit of $1.86 (15.32%) receiving and performance score of 25.54.

Average potential price target upside

of $46.99 (15.05%) on TMO (THERMO FISHER SCIENTIFIC).
of $31.48 (26.62%) on PKI (PERKINELMER).
of $18.65 (26.5%) on BRKS (BROOKS AUTOMATION).

BRKR Bruker BRKS Brooks Automation DHR Danaher NEO NeoGenomics TMO Thermo Fisher Scientific A Agilent Technologies CYRX Cryoport AZTA Azenta VCYT Veracyte GHDX Genomic Health MYGN Myriad Genetics OCX OncoCyte Corp PKI PerkinElmer

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

John Sourbeer (UBS)